Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BAVARIAN NORDIC A S. We currently have 5 research reports from 1 professional analysts.
|23Feb17 15:21||GNW||Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV|
|17Jan17 07:00||GNW||Henrik Birk Appointed Chief Operating Officer of Bavarian Nordic|
|04Jan17 13:26||GNW||Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study|
|03Jan17 10:24||GNW||Bavarian Nordic Upgrades its Expectations for 2016 Year-end Cash Preparedness|
|29Dec16 12:00||GNW||Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer|
|23Nov16 14:23||GNW||Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine|
|23Nov16 09:06||GNW||Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise|
Frequency of research reports
Research reports on
BAVARIAN NORDIC A S
BAVARIAN NORDIC A S
Progressing at cruising speed
02 Jun 16
Following a $100m private placement, Bavarian Nordic is ready to push its pipeline forward and create long-term value. Smallpox vaccine Imvamune is being stockpiled by the US and Canadian governments and Prostvac is advancing towards top-line Phase III data in 2017. The MVA-BN RSV vaccine is progressing towards mid-stage studies, while Phase II trials of CV-301 and Prostvac in combination with checkpoint inhibitors will start by mid-year. Our updated valuation of DKK13.4bn includes RSV and the latest bulk Imvamune order.
Private placement trumps IPO
26 Apr 16
The current weak US IPO conditions have resulted in a slight change of plan for Bavarian Nordic. It recently shelved its US listing plans and instead completed a private share placement, which raised c $100m vs. the expected $86m in the F-1 filing. New funds will be used for the same purposes as the IPO, namely advancing the development of CV-301, MVABN RSV and for capex. Prostvac has passed its first interim analysis and the Phase III trial will continue without modification.
Seeking a cash injection from the US
17 Feb 16
Bavarian Nordic’s intention to list on NASDAQ is a strategic move to broaden its appeal to US investors and raise additional funds to accelerate clinical development of multi-tumor cancer immunotherapy CV-301 and respiratory syncytial virus vaccine MVA-BN RSV and to expand its manufacturing capacity. As a well-funded revenue generating company, it should still appeal to investors despite market headwinds. While pricing is to be determined, the likely timing of the proposed IPO represents an attractive entry point for US investors ahead of a newsflow-rich 2016.
Advancing the pipeline with start of RSV trial
21 Aug 15
Bavarian Nordic has now commenced the planned Phase I study of MVABN RSV. Advancing the earlier-stage pipeline is one of Bavarian Nordic’s key priorities, hence this represents an important step. RSV could be a significant opportunity, particularly in adults, and we expect Bavarian to consider partnering, albeit not until at least Phase II. Our valuation, which does not yet include RSV owing to its early stage of development, is largely unchanged at DKK12.6bn.
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals